William Ridgway Appointed Director of UC's Division of Immunology
William Ridgway, MD, has been appointed director of the division of immunology at the University of Cincinnati (UC)
Ridgway was previously an associate professor of medicine, with tenure, in the division of rheumatology and clinical immunology at the University of Pittsburgh School of Medicine where he researched the genetics and cellular immunology of autoimmunity. He focuses primarily on investigating mouse models with spontaneous autoimmune syndromes such as type 1 diabetes and autoimmune liver disease. He was also a principal investigator within the National Institutes of Health (NIH) funded Autoimmunity Center of Excellence at the
From 1998 to 2003, Ridgway served as chief of the rheumatology division at the
I am very excited to have Dr. Ridgway lead UCs division of immunology, says David Stern, MD, vice president for health affairs at UC and dean of the
He will be a welcome addition to the leadership team of the
Ridgway received his medical degree from the
He has collaborated with many physicians, nationally and internationally, on basic research, particularly in the areas of autoimmunity and autoimmune phenotypes. Additionally, Ridgway has retained repeated research support through grants from the NIH.
During his career, Ridgway has received several distinguished awards including the
highly competitive Pfizer Scholars Grant for new faculty and Juvenile Diabetes Foundation International Career Development Award. He is a member of the
I am pleased and honored to join the Division of Immunology at University of Cincinnati Academic Health Center, Ridgway says. I look forward to starting new research initiatives in lupus, allergy and the immunogenetics of autoimmune disease.
Ridgway replaces John Houk, MD, interim director of the immunology division.
Related Stories
UC experts present neurology research at national conference
April 17, 2026
University of Cincinnati researchers will present abstracts at the 2026 American Academy of Neurology Annual Meeting April 18 to 22 in Chicago.
AI advances in the liver disease field
April 15, 2026
MASH represents the advanced inflammatory form of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as nonalcoholic fatty liver disease), where fat accumulation in the liver triggers fibrosis and progressive liver injury. According to a recent MedCentral article, more AI-based clinical assessment tools in MASH are needed.
UC Graduate College honors 2026 Graduate Student Research Award recipients during Research + Innovation Week
April 15, 2026
The University of Cincinnati Graduate College is proud to announce the recipients of the 2026 Graduate Student Research Awards, recognizing doctoral students whose research, scholarship, and creative work demonstrate excellence in innovation, impact and interdisciplinarity.